| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 10/03/2002 | CA2438206A1 Transporters and ion channels |
| 10/02/2002 | EP1244798A2 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
| 10/02/2002 | EP1244685A1 Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies |
| 10/02/2002 | EP1244666A1 Imidazopyrimidinyl and imidazopyridinyl derivatives |
| 10/02/2002 | EP1244626A2 Caspase inhibitors and uses thereof |
| 10/02/2002 | EP1244461A2 INHIBITION OF GSK-3$g(b) |
| 10/02/2002 | EP1098894B1 Fkbp inhibitors |
| 10/02/2002 | EP0804196B1 Use of serotonin antagonists (5ht 3) for treating fibromyalgia |
| 10/02/2002 | CN1372569A Keratinocyte growth factor-2 |
| 10/02/2002 | CN1372557A Neurotrophin production/secretion promoting agent |
| 10/01/2002 | US6458846 Ion channel modulating agents |
| 10/01/2002 | US6458837 Lipophilic diesters of chelating agents |
| 10/01/2002 | US6458813 2-cyclohexyloxy-5-(2-chlorophenylcarbonylamino)pyridine, for example; treating inflammation, pain, diabetes, cancer |
| 10/01/2002 | US6458383 Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
| 10/01/2002 | US6458374 Methods and compositions for treating chronic disorders using optically pure (+)-bupropion |
| 09/27/2002 | CA2378876A1 Cyclohexylamine derivatives as subtype selective n-methyl-d-aspartate antagonists |
| 09/26/2002 | WO2002074913A2 Nucleic acid-associated proteins |
| 09/26/2002 | WO2002074346A2 Targeting chemical compounds to cells |
| 09/26/2002 | WO2002062999A8 Proteins and nucleic acids encoding same |
| 09/26/2002 | WO2002055064A3 Mucopolysaccharidosis therapies |
| 09/26/2002 | WO2002000710A3 B7-like molecules and uses thereof |
| 09/26/2002 | WO2001098332A3 Secreted redox proteins |
| 09/26/2002 | WO2001087343A3 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| 09/26/2002 | WO2001083775A3 Proteases |
| 09/26/2002 | WO2001019977A9 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 09/26/2002 | US20020137932 Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma |
| 09/26/2002 | US20020137798 Treatment of disorders secondary to organic impairments |
| 09/26/2002 | US20020137778 Anticancer, antiarthritic, and antiinflammatory agents |
| 09/26/2002 | US20020137749 Formulation for menopausal women |
| 09/26/2002 | US20020137717 Use of chimeric mutational vectors to change endogenous nucleotide sequences in solid tissues |
| 09/26/2002 | US20020137170 Dual-specificity protein tyrosine phosphatases that dephosphorylate both phosphotyrosine and phosphothreonine/serine residues |
| 09/26/2002 | US20020137049 Pablo, a polypeptide that interacts with Bcl-xL, and uses related thereto |
| 09/26/2002 | CA2441111A1 Method for targeting chemical compounds to cells and pharmaceutical compositions used therein |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/25/2002 | EP1242624A2 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 09/25/2002 | EP1242590A2 Human lyases and associated proteins |
| 09/25/2002 | EP1242449A1 Modified adenovirus fibre and uses |
| 09/25/2002 | EP1242407A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242383A1 Aza compounds having neuronal activity |
| 09/25/2002 | EP1242120A2 Combinations of growth factors and i:upa or i:mmp for the treatment of damaged tissue |
| 09/25/2002 | EP1242089A2 Use of adatanserin for the treatment of neurodegenerative conditions |
| 09/25/2002 | EP1242067A2 Calcium formate for use as a phosphorus binder and a dietary supplement |
| 09/25/2002 | EP0986390B1 Pharmaceutical compositions containing cinchonine dichlorhydrate |
| 09/25/2002 | CN1371424A Activatable recombinant neurotoxins |
| 09/25/2002 | CN1370526A Treating method of nuclear factor-KB mediated diseases and dysfuction |
| 09/25/2002 | CN1091446C Colchicine derivatives, use thereof and formulations containing them |
| 09/24/2002 | US6455564 Oral administration of (5r)-(methylamino)-5,6-dihydro-4h-imidazo(4,5,1-ij)quinolin-2( '1h)-one or -thione |
| 09/24/2002 | US6455562 Cyclic AMP-specific phosphodiesterase inhibitors |
| 09/24/2002 | US6455561 Administering benzofuran derivative for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase iv or tumour necrosis factor |
| 09/24/2002 | US6455525 Heterocyclic substituted pyrazolones |
| 09/24/2002 | US6455502 Compounds and compositions as protease inhibitors |
| 09/24/2002 | US6455044 5c8 antigen |
| 09/20/2002 | WO2001070704A1 Novel imidazole derivatives with anti-inflammatory activity |
| 09/20/2002 | CA2403732A1 Novel imidazole derivatives with anti-inflammatory activity |
| 09/19/2002 | WO2002073208A2 Anti-epileptogenic agents |
| 09/19/2002 | WO2002072826A2 Neurotrophic factors |
| 09/19/2002 | WO2002072822A2 Als2 gene and amyotrophic lateral sclerosis type 2 |
| 09/19/2002 | WO2002072608A2 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS |
| 09/19/2002 | WO2002072579A1 Triazolopyridines as anti-inflammatory agents |
| 09/19/2002 | WO2002072202A1 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| 09/19/2002 | WO2002072025A2 Improving postsynaptic response by a combination of 4-minopyridine and agonist |
| 09/19/2002 | WO2002072019A2 Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases |
| 09/19/2002 | WO2002050028A3 Substituted benzoindoles as spla2 inhibitors |
| 09/19/2002 | WO2001072702A3 Amidino compounds useful as nitric oxide synthase inhibitors |
| 09/19/2002 | US20020133023 Antitumor agents, osteoporosis |
| 09/19/2002 | US20020132852 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use |
| 09/19/2002 | US20020132849 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 09/19/2002 | US20020132833 Caspase inhibitors and uses thereof |
| 09/19/2002 | US20020132763 Deuterated cyclosporine analogs and their use as immunomodulating agents |
| 09/19/2002 | CA2440834A1 Anti-epileptogenic agents |
| 09/19/2002 | CA2437960A1 Als2 gene and amyotrophic lateral sclerosis type 2 |
| 09/19/2002 | CA2437958A1 Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors |
| 09/18/2002 | EP1241254A1 Apoptosis inhibitory polypeptide, gene and polynucleotide encoding it and compositions containing the same |
| 09/18/2002 | EP1240197A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 09/18/2002 | EP1240194A2 Novel human protein kinases and protein kinase-like enzymes |
| 09/18/2002 | EP1240160A1 Substituted pyridazines having cytokine inhibitory activity |
| 09/18/2002 | EP1240153A1 Aminothiazole inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1240152A1 Ox(adi)azolyl-hydroxamic acids useful as procollagen c-proteinase inhibitors |
| 09/18/2002 | EP1240144A2 Compound having effect of promoting neuron differentiation |
| 09/18/2002 | EP1240143A1 New modulators of dopamine neurotransmission |
| 09/18/2002 | EP1239881A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239845A2 Hydroxide-releasing agents as skin permeation enhancers |
| 09/18/2002 | EP1239843A1 New (aminopropyl)methylphosphinic acids |
| 09/18/2002 | CN1370174A 2,3-benzodiazepine derivatives |
| 09/18/2002 | CN1370163A Imidazo [1,2-A] pyridine and pyrazolo [2,3-a] pyridine derivatives |
| 09/18/2002 | CN1370154A Aminothiazole derivatives and their use as CRF receptor ligands |
| 09/18/2002 | CN1370073A Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
| 09/17/2002 | US6452044 Benzenedicarboxylic acid derivatives |
| 09/17/2002 | US6451994 Polypeptides, polynucleotides; drug screening; diagnosing alzheimer*s, parkinson*s, huntington*s, and creutzfelt-jacob disease; amyotrophic lateral sclerosis, cystic fibrosis |
| 09/17/2002 | US6451819 Pyrrolidine-3-yl-sulfanyl, or sufonyl or sufinyl derivatives used in the treatment of neurodegenerative diseases |
| 09/17/2002 | US6451818 Therapeutic use of 1,6-dimethyl-8β-hydroxymethyl-10α-methoxyergoline |
| 09/17/2002 | US6451786 Tyrosine kinase inhibitors |
| 09/17/2002 | US6451310 Preventing t cell activation of b cells by administering antibody cabable of binding protein recognized by monoclonal antibody 5c8 |
| 09/17/2002 | CA2080272C Cyclic vasoactive peptides |
| 09/12/2002 | WO2002070741A2 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna |
| 09/12/2002 | WO2002070708A2 Glutamate receptor modulatory proteins and nucleic acids encoding them |
| 09/12/2002 | WO2002070669A2 Secreted proteins |
| 09/12/2002 | WO2002070657A2 93870, a human g-protein coupled receptor and uses therefor |
| 09/12/2002 | WO2002070563A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070559A2 Nuclear hormone receptor ligand binding domains |